Market Overview:

The Europe idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 8.00% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Idiopathic pulmonary fibrosis (IPF) is a persistent lung infection that causes scarring of the lungs. This hampers the oxygen-carrying functionality of the organ, thereby resulting in breathing difficulties. Some of the common symptoms include a persistent dry cough, fatigue, loss of appetite, and swollen limbs. IPF is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. It can be treated by prescribing anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.

Europe Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The Europe IPF treatment market is primarily being driven by the increasing prevalence of chronic lung and fibrotic diseases, especially in the geriatric population. This can be attributed to changing living standards, high smoking rates, and increasing environment pollutants. Other than this, increasing health consciousness amongst consumers and rising awareness regarding the presence of effective IPF preventive and management strategies are catalyzing the market growth. In line with this, increasing government expenditures for the development of existing healthcare systems and rapid advancements in diagnostic techniques are acting as another growth-inducing factor. The implementation of favorable regulatory policies and continuous investments in research and development (R&D) activities for introducing novel medicines are further creating a positive outlook for the market in the region.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the Europe idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
   

Breakup by End User:

• Hospitals
• Long-term Care Facilities
• Others
   

Breakup by Country:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Others
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Key Questions Answered in This Report:

• How has the Europe idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Europe idiopathic pulmonary fibrosis treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the Europe idiopathic pulmonary fibrosis treatment market and who are the key players?
• What is the degree of competition in the industry?